首页> 美国卫生研究院文献>BioMed Research International >Biomedical Applications of Fermenticin HV6b Isolated from Lactobacillus fermentum HV6b MTCC10770
【2h】

Biomedical Applications of Fermenticin HV6b Isolated from Lactobacillus fermentum HV6b MTCC10770

机译:发酵乳杆菌HV6b MTCC10770中分离的发酵菌HV6b的生物医学应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fermenticin HV6b is a class IIa antimicrobial peptide produced by Lactobacillus fermentum HV6b MTCC 10770 isolated from human vaginal ecosystem. It shows growth inhibition of a wide range of opportunistic pathogens of humans, for example, Bacteroides, Gardnerella vaginalis, Mobiluncus, Staphylococci, and Streptococci, associated with bacterial vaginosis in humans. It does possess an impressive sperm immobilization and spermicidal activity tested against human sperms which makes it an attractive proposition for formulating antibacterial vaginosis and contraceptive products. Apart from this, in vitro studies conducted against four different tissue models have indicated its potential to be used as a component of anticancerous drug therapy as it is reported to induce apoptosis in cancerous cells. This information could be integrated in future studies focusing on in vivo assessment of anticancerous activity of lactic acid bacterial toxins or bacteriocins.
机译:Fermenticin HV6b是由发酵乳杆菌HV6b MTCC 10770分离自人类阴道生态系统而产生的IIa类抗菌肽。它显示出与人类细菌性阴道病相关的人类多种机会性病原体的生长抑制,例如,拟杆菌,阴道加德纳菌,美孚力士,葡萄球菌和链球菌。它确实具有令人印象深刻的精子固定和针对人类精子的杀精活性,这使其成为配制抗菌性阴道病和避孕产品的诱人命题。除此之外,针对四种不同组织模型进行的体外研究表明,它的潜力有可能被用作抗癌药物治疗的组成部分,因为据报道它可诱导癌细胞的凋亡。该信息可以整合到将来的研究中,集中在体内评估乳酸菌毒素或细菌素的抗癌活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号